Physician profile
Patrick Timothy Bringardner
NPI 1154877025
$1,230.87
in general payments reported to CMS, 2019-2025
20 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $207 · 2023: $371 · 2024: $384 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,008.36 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $220.75 | 2022-2024 | Shingrix, Nucala, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $163.74 | 2023-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $145.06 | 2024 | Voquezna |
| Abbvie INC. | $138.70 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $85.44 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Dexcom, INC. | $77.14 | 2023-2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $56.06 | 2022-2024 | |
| Amgen INC. | $49.87 | 2023-2024 | Otezla, Repatha |
| Aimmune Therapeutics, INC. | $46.42 | 2025 | Zenpep |
| Pfizer INC. | $34.57 | 2023 | |
| Exact Sciences Corporation | $33.33 | 2025 | The Cologuard Plus Collection Kit |
| Vertex Pharmaceuticals Incorporated | $29.50 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $21.77 | 2024 | Camzyos |
| Indivior INC. | $21.39 | 2024 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.38 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $19.81 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.63 | 2025 | Gvoke Hypopen |
| Neurelis, INC. | $18.78 | 2024 | Valtoco |
| Tandem Diabetes Care, INC. | $14.48 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Janssen Pharmaceuticals, INC | $14.05 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Bringardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.